Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson's disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications. Hallucinations and delusions improved significantly in all patients. Donezepil was overall well tolerated, but a deterioration in motor disability was noted in 2 out of 8 patients.
Fabbrini
G
G
Department of Neurological Sciences, La Sapienza University, Viale del'Università 30, I-00185 Rome, Italy.
Barbanti
P
P
Aurilia
C
C
Pauletti
C
C
Lenzi
G L
GL
Meco
G
G
D000368:Aged; D000369:Aged, 80 and over; D020532:Basal Nucleus of Meynert / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002799:Cholinergic Fibers / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D003702:Delusions / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D000077265:Donepezil; D005260:Female; D006212:Hallucinations / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007189:Indans / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009068:Movement / Q000187:drug effects; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D020018:Sexual Dysfunctions, Psychological / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D016896:Treatment Outcome
D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D000077265:Donepezil